Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of tubatoxin in preparation of drugs treating acute kidney injury

A technology of acute kidney injury and rotenone, which is applied in the field of new drug use, to achieve the effect of improving renal function indicators and strong poisonous effect

Active Publication Date: 2018-02-02
NANJING CHILDRENS HOSPITAL
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Complements existing treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of tubatoxin in preparation of drugs treating acute kidney injury
  • Use of tubatoxin in preparation of drugs treating acute kidney injury
  • Use of tubatoxin in preparation of drugs treating acute kidney injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1 Rotenone can reduce serum renal function indicators in mice with acute kidney injury induced by excessive APAP

[0023] Twenty-one mice were randomly divided into three groups, normal control group, APAP-induced renal injury model group, and APAP-induced acute kidney injury plus rotenone treatment group, with 7 mice in each group. Both the normal control group and the model group had a normal diet, and the administration group received 250 ppm rotenone in the feed. After 24 hours of modeling, detect serum renal function indicators of mice: blood urea nitrogen (BUN) and creatinine (Cr), such as figure 1 As shown, the serum BUN and Cr of the mice in the rotenone treatment group were significantly lower than those in the APAP model group, with a statistical difference.

Embodiment 2

[0024] Example 2 Rotenone can reduce the degree of renal pathological damage in mice with acute kidney injury induced by excessive APAP

[0025] Twenty-one mice were randomly divided into three groups, normal control group, APAP-induced renal injury model group, and APAP-induced renal injury plus rotenone treatment group, with 7 mice in each group. Both the normal control group and the model group had a normal diet, and the treatment group was supplemented with 250ppm rotenone in the feed. After 24 hours of modeling, the mouse kidneys were fixed with 4% polyformaldehyde, embedded in paraffin, sectioned, and then stained with PAS. Microscopic examination results showed that the brush border of normal kidney tissue was clear and obvious, and the size of glomeruli was normal. , while the nephroscopy of the mice in the model group showed that the brush border of the renal tubules was partially lost and unclear, and the glomerulus was enlarged. The pathological changes of the kidn...

Embodiment 3

[0026] Example 3 Rotenone can reduce kidney inflammation in mice with acute kidney injury induced by excessive APAP

[0027] Twenty-one mice were randomly divided into three groups, normal control group, APAP-induced renal injury model group, and APAP-induced renal injury plus rotenone treatment group, with 7 mice in each group. Both the normal control group and the model group had a normal diet, and the administration group received 250 ppm rotenone in the feed. After 24 hours of modeling, kidney tissue was taken and RNA was extracted, and then the mRNA transcription levels of inflammation-related factors (IL-6, MCP-1 and ICAM-1) in the kidney were detected by reverse transcription and real-time fluorescent quantitative PCR. The results showed that, The transcription levels of these inflammatory factors in the kidneys of mice in the APAP model group were significantly increased, while in the kidneys of mice treated with rotenone, the transcription levels of these inflammatory...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the use of tubatoxin in preparation of drugs treating acute kidney injury. After treatment with a small dose (250ppm) of tubatoxin, the mouse kidney injury situation can be obviously improved, and the levels of blood urea nitrogen (BUN) enzyme and creatinine (Cr) are obviously lowered.

Description

technical field [0001] The invention relates to a new application of rotenone, in particular to the use of rotenone in treating acute kidney injury, and belongs to the field of new application of medicines. Background technique [0002] The kidneys are responsible for the metabolism and detoxification of the human body. Calculated on the basis that a person excretes 1.5-2 liters of urine per day, the kidneys actually have to deal with 180 liters of primary urine every day, which is about 100 times that of the former. The metabolism and excretion of drugs also rely on the kidneys, and the molecular weight, fat solubility, and protein affinity of drugs will affect renal metabolism and form accumulation. In the filtration process of the kidney, once the drug accumulates in the kidney repeatedly and for a long time, it is easy to cause kidney damage. [0003] Acute kidney injury (AKI) is a group of clinical syndromes, which refers to sudden (within 1-7d) and sustained (>24h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61P13/12
CPCA61K31/352
Inventor 贾占军华虎张爱华丁桂霞张正磊葛许华
Owner NANJING CHILDRENS HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com